Tom 13, Nr 4 (2017)
Artykuł przeglądowy
Opublikowany online: 2018-01-05

dostęp otwarty

Wyświetlenia strony 1346
Wyświetlenia/pobrania artykułu 6891
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Zaburzenia snu w chorobie Alzheimera

Mariusz Siemiński1
Pol. Przegl. Neurol 2017;13(4):173-185.

Streszczenie

Zaburzenia snu są istotnym, lecz często zaniedbywanym elementem obrazu klinicznego choroby Alzheimera (AD, Alzheimer’s disease). Istnieją przesłanki pozwalające sądzić, że zaburzenia snu (szerzej — zaburzenia rytmu snu i czuwania) mogą promować zjawiska sprzyjające rozwojowi procesu neurodegeneracyjnemu. Natomiast zmiany neuropatologiczne zachodzące w przebiegu choroby mogą prowadzić do zaburzeń rytmu okołodobowego. U chorych z AD współwystępują pierwotne zaburzenia snu. Leki stosowane w terapii AD nie pozostają bez wpływu na sen. Zrozumienie mechanizmów łączących zaburzenia snu z neurodegeneracją może pomóc w planowaniu działań profilaktycznych. Rozpoznanie zaburzeń snu wymaga przede wszystkim zebrania właściwego wywiadu, a w uzasadnionych przypadkach — wykorzystania aktygrafii bądź polisomnografii. Leczenie zaburzeń snu, zaplanowane adekwatnie do rozpoznania, może poprawić stan pacjenta pod względem emocjonalnym, poznawczym i behawioralnym. Lekarz i opiekun pacjenta z AD dysponują różnymi terapeutycznymi metodami farmakologicznymi i niefarmakologicznymi, których umiejętne zastosowanie może przynieść pozytywny efekt.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Hippius H, Neundörfer G. The discovery of Alzheimer's disease. Dialogues Clin Neurosci. 2003; 5(1): 101–108.
  2. Guarnieri B, Adorni F, Musicco M, et al. Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: a multicenter Italian clinical cross-sectional study on 431 patients. Dement Geriatr Cogn Disord. 2012; 33(1): 50–58.
  3. Little JT, Satlin A, Sunderland T, et al. Sundown syndrome in severely demented patients with probable Alzheimer's disease. J Geriatr Psychiatry Neurol. 1995; 8(2): 103–106.
  4. Volicer L, Harper DG, Manning BC, et al. Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry. 2001; 158(5): 704–711.
  5. Pollak CP, Perlick D, Linsner JP, et al. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health. 1990; 15(2): 123–135.
  6. Dale MC, Burns A, Panter L, et al. Factors affecting survival of elderly nursing home residents. Int J Geriatr Psychiatry. 2001; 16(1): 70–76, doi: 10.1002/1099-1166(200101)16:1<70::aid-gps277>3.0.co;2-6.
  7. Moran M, Lynch CA, Walsh C, et al. Sleep disturbance in mild to moderate Alzheimer's disease. Sleep Med. 2005; 6(4): 347–352.
  8. Villa C, Ferini-Strambi L, Combi R. The Synergistic Relationship between Alzheimer's Disease and Sleep Disorders: An Update. J Alzheimers Dis. 2015; 46(3): 571–580.
  9. Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult - a mini-review. Gerontology. 2010; 56(2): 181–189.
  10. Espiritu JR. Aging-related sleep changes. Clin Geriatr Med. 2008; 24(1): 1–14, v.
  11. Ohayon MM, Carskadon MA, Guilleminault C, et al. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004; 27(7): 1255–1273.
  12. Cho K. Chronic 'jet lag' produces temporal lobe atrophy and spatial cognitive deficits. Nat Neurosci. 2001; 4(6): 567–568.
  13. Peter-Derex L, Yammine P, Bastuji H, et al. Sleep and Alzheimer's disease. Sleep Med Rev. 2015; 19: 29–38.
  14. Schlosser Covell GE, Dhawan PS, Lee Iannotti JK, et al. Disrupted daytime activity and altered sleep-wake patterns may predict transition to mild cognitive impairment or dementia: a critically appraised topic. Neurologist. 2012; 18(6): 426–429.
  15. Lim ASP, Ellison BA, Wang JL, et al. Sleep is related to neuron numbers in the ventrolateral preoptic/intermediate nucleus in older adults with and without Alzheimer's disease. Brain. 2014; 137(Pt 10): 2847–2861.
  16. Nebes RD, Buysse DJ, Halligan EM, et al. Self-reported sleep quality predicts poor cognitive performance in healthy older adults. J Gerontol B Psychol Sci Soc Sci. 2009; 64(2): 180–187.
  17. Keage HA, Banks S, Yang KL, et al. What sleep characteristics predict cognitive decline in the elderly? Sleep Med. 2012; 13(7): 886–892.
  18. Potvin O, Lorrain D, Forget H, et al. Sleep quality and 1-year incident cognitive impairment in community-dwelling older adults. Sleep. 2012; 35(4): 491–499.
  19. Niu J, Han H, Wang Y, et al. Sleep quality and cognitive decline in a community of older adults in Daqing City, China. Sleep Med. 2016; 17: 69–74.
  20. Lim ASP, Kowgier M, Yu L, et al. Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons. Sleep. 2013; 36(7): 1027–1032.
  21. Ooms S, Overeem S, Besse K, et al. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014; 71(8): 971–977.
  22. Cedernaes J, Osorio RS, Varga AW, et al. Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer's disease. Sleep Med Rev. 2017; 31: 102–111.
  23. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013; 342(6156): 373–377.
  24. Di Meco A, Joshi YB, Praticò D. Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles. Neurobiol Aging. 2014; 35(8): 1813–1820.
  25. Rothman SM, Herdener N, Frankola KA, et al. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer's disease. Brain Res. 2013; 1529: 200–208.
  26. Sultana R, Butterfield D. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis. 2010; 19(1): 341–353.
  27. Zhang J, Zhu Y, Zhan G, et al. Extended wakefulness: compromised metabolics in and degeneration of locus ceruleus neurons. J Neurosci. 2014; 34(12): 4418–4431.
  28. Silva RH, Abílio VC, Takatsu AL, et al. Role of hippocampal oxidative stress in memory deficits induced by sleep deprivation in mice. Neuropharmacology. 2004; 46(6): 895–903.
  29. He J, Hsuchou H, He Yi, et al. Sleep restriction impairs blood-brain barrier function. J Neurosci. 2014; 34(44): 14697–14706.
  30. Winkler EA, Nishida Y, Sagare AP, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015; 18(4): 521–530.
  31. Coogan AN, Schutová B, Husung S, et al. The circadian system in Alzheimer's disease: disturbances, mechanisms, and opportunities. Biol Psychiatry. 2013; 74(5): 333–339.
  32. Stopa EG, Volicer L, Kuo-Leblanc V, et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol. 1999; 58(1): 29–39.
  33. Harper DG, Stopa EG, McKee AC, et al. Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease. Neurobiol Aging. 2004; 25(6): 771–781.
  34. Harper DG, Stopa EG, Kuo-Leblanc V, et al. Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia. Brain. 2008; 131(Pt 6): 1609–1617.
  35. Mahlberg R, Walther S, Kalus P, et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. Neurobiol Aging. 2008; 29(2): 203–209.
  36. Liu RY, Zhou JN, van Heerikhuize J, et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab. 1999; 84(1): 323–327.
  37. Zhou JN, Liu RY, Kamphorst W, et al. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003; 35(2): 125–130.
  38. Lahiri DK, Chen D, Ge YW, et al. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J Pineal Res. 2004; 36(4): 224–231.
  39. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem. 2003; 85(5): 1101–1108.
  40. Rose KM, Beck C, Tsai PF, et al. Sleep disturbances and nocturnal agitation behaviors in older adults with dementia. Sleep. 2011; 34(6): 779–786.
  41. Gehrman PR, Martin JL, Shochat T, et al. Sleep-disordered breathing and agitation in institutionalized adults with Alzheimer disease. Am J Geriatr Psychiatry. 2003; 11(4): 426–433.
  42. Djonlagic I, Guo M, Matteis P, et al. Untreated sleep-disordered breathing: links to aging-related decline in sleep-dependent memory consolidation. PLoS One. 2014; 9(1): e85918.
  43. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014; 15(8): 860–873.
  44. Klaffke S, Staedt J. Sundowning and circadian rhythm disorders in dementia. Acta Neurol Belg. 2006; 106(4): 168–175.
  45. Etcher L, Whall A, Kumar R, et al. Nonlinear indices of circadian changes in individuals with dementia and aggression. Psychiatry Res. 2012; 199(1): 77–78.
  46. Gallagher-Thompson D, Brooks JO, Bliwise D, et al. The relations among caregiver stress, J Am Geriatr Soc. 1992; 40(8): 807–810.
  47. Kanbayashi T, Sugiyama T, Aizawa R, et al. Effects of donepezil (Aricept) on the rapid eye movement sleep of normal subjects. Psychiatry Clin Neurosci. 2002; 56(3): 307–308.
  48. Tractenberg RE, Singer CM, Cummings JL, et al. The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J Sleep Res. 2003; 12(4): 331–337.
  49. Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med. 2013; 9(5): 475–480.
  50. Ancoli-Israel S, Clopton P, Klauber MR, et al. Use of wrist activity for monitoring sleep/wake in demented nursing-home patients. Sleep. 1997; 20(1): 24–27.
  51. Paavilainen P, Korhonen I, Lötjönen J, et al. Circadian activity rhythm in demented and non-demented nursing-home residents measured by telemetric actigraphy. J Sleep Res. 2005; 14(1): 61–68.
  52. Kushida CA, Nichols DA, Holmes TH, et al. Effects of continuous positive airway pressure on neurocognitive function in obstructive sleep apnea patients: The Apnea Positive Pressure Long-term Efficacy Study (APPLES). Sleep. 2012; 35(12): 1593–1602.
  53. Rosenzweig I, Glasser M, Crum WR, et al. Changes in Neurocognitive Architecture in Patients with Obstructive Sleep Apnea Treated with Continuous Positive Airway Pressure. EBioMedicine. 2016; 7: 221–229.
  54. Ancoli-Israel S, Palmer BW, Cooke JR, et al. Cognitive effects of treating obstructive sleep apnea in Alzheimer's disease: a randomized controlled study. J Am Geriatr Soc. 2008; 56(11): 2076–2081.
  55. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016; 87(24): 2585–2593.
  56. Stoner SC, Dahmen MM, Makos M, et al. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease. Ann Pharmacother. 2009; 43(9): 1426–1432.
  57. Singer C, Tractenberg RE, Kaye J, et al. Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003; 26(7): 893–901.
  58. Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014; 9: 947–961.
  59. Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry. 2009; 17(2): 166–169.
  60. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst Rev. 2014(3): CD009178.
  61. Zhang W, Chen Xy, Su Sw, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016; 37(1): 57–65.
  62. Defrancesco M, Marksteiner J, Fleischhacker WW, et al. Use of Benzodiazepines in Alzheimer's Disease: A Systematic Review of Literature. Int J Neuropsychopharmacol. 2015; 18(10): pyv055.
  63. Yin Y, Liu Y, Zhuang J, et al. Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances. Pharmacology. 2015; 96(3-4): 155–162.
  64. Meguro K, Meguro M, Tanaka Y, et al. Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease. J Geriatr Psychiatry Neurol. 2004; 17(2): 61–67.
  65. Wirz-Justice A, Werth E, Savaskan E, et al. Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Dis Assoc Disord. 2000; 14(4): 212–215.
  66. Savaskan E, Schnitzler C, Schröder C, et al. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol. 2006; 9(5): 507–516.
  67. Alessi CA, Martin JL, Webber AP, et al. Randomized, controlled trial of a nonpharmacological intervention to improve abnormal sleep/wake patterns in nursing home residents. J Am Geriatr Soc. 2005; 53(5): 803–810.
  68. Richards KC, Beck C, O'Sullivan PS, et al. Effect of individualized social activity on sleep in nursing home residents with dementia. J Am Geriatr Soc. 2005; 53(9): 1510–1517.
  69. Figueiro MG, Plitnick BA, Lok A, et al. Tailored lighting intervention improves measures of sleep, depression, and agitation in persons with Alzheimer's disease and related dementia living in long-term care facilities. Clin Interv Aging. 2014; 9: 1527–1537.
  70. Burns A, Allen H, Tomenson B, et al. Bright light therapy for agitation in dementia: a randomized controlled trial. Int Psychogeriatr. 2009; 21(4): 711–721.
  71. Dowling GA, Burr RL, Van Someren EJW, et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc. 2008; 56(2): 239–246.
  72. McCurry SM, Pike KC, Vitiello MV, et al. Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer's disease: results of a randomized, controlled trial. J Am Geriatr Soc. 2011; 59(8): 1393–1402.
  73. Moraes Wd, Poyares DR, Guilleminault C, et al. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep. 2006; 29(2): 199–205.
  74. Moraes W, Poyares D, Sukys-Claudino L, et al. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest. 2008; 133(3): 677–683.
  75. Ishikawa I, Shinno H, Ando N, et al. The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer's disease. Acta Neuropsychiatr. 2016; 28(3): 157–164.